Journal of Ovarian Research This Provisional PDF corresponds to the article as it appeared upon acceptance Fully formatted PDF and full text (HTML) versions will be made available soon Gene Expression and Pathway Analysis of Ovarian Cancer Cells Selected for Resistance to Cisplatin, Paclitaxel, or Doxorubicin Journal of Ovarian Research 2011, 4:21 doi:10.1186/1757-2215-4-21 Cheryl A Sherman-Baust (shermanbaustc@mail.nih.gov) Kevin G Becker (BeckerK@grc.nia.nih.gov) William H Wood III (WoodW@grc.nia.nih.gov) Yongqing Zhang (zhangyon@grc.nia.nih.gov) Patrice J Morin (morinp@mail.nih.gov) ISSN Article type 1757-2215 Research Submission date 12 October 2011 Acceptance date December 2011 Publication date December 2011 Article URL http://www.ovarianresearch.com/content/4/1/21 This peer-reviewed article was published immediately upon acceptance It can be downloaded, printed and distributed freely for any purposes (see copyright notice below) Articles in Journal of Ovarian Research are listed in PubMed and archived at PubMed Central For information about publishing your research in Journal of Ovarian Research or any BioMed Central journal, go to http://www.ovarianresearch.com/authors/instructions/ For information about other BioMed Central publications go to http://www.biomedcentral.com/ © 2011 Sherman-Baust et al ; licensee BioMed Central Ltd This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin Cheryl A Sherman-Baust1, Kevin G Becker2, William H.Wood, III2, Yongqing Zhang2, and Patrice J Morin1,3* Laboratory of Molecular Biology and Immunology, National Institute on Aging, Baltimore MD 21224, USA Research Resource Branch, National Institute on Aging, Baltimore MD 21224, USA Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA *corresponding author: Patrice J Morin, Ph.D Laboratory of Cellular and Molecular Biology, National Institute on Aging, NIH Biomedical Research Center, 251 Bayview Blvd., Suite 100, Room 6C228, Baltimore, MD 21224, USA; 410-558-8386; Email: morinp@mail.nih.gov Abstract Background: Resistance to current chemotherapeutic agents is a major cause of therapy failure in ovarian cancer patients, but the exact mechanisms leading to the development of drug resistance remain unclear Methods: To better understand mechanisms of drug resistance, and possibly identify novel targets for therapy, we generated a series of drug resistant ovarian cancer cell lines through repeated exposure to three chemotherapeutic drugs (cisplatin, doxorubicin, or paclitaxel), and identified changes in gene expression patterns using Illumina wholegenome expression microarrays Validation of selected genes was performed by RT-PCR and immunoblotting Pathway enrichment analysis using the KEGG, GO, and Reactome databases was performed to identify pathways that may be important in each drug resistance phenotype Results: A total of 845 genes (p